Profil

Kahvecioglu Zehra Cagla

Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service de Biologie humaine et Toxicologie

Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Biologie humaine et Toxicologie

ORCID
0009-0009-2015-0712
Main Referenced Co-authors
LAURENT, Sophie  (11)
BURTEA, Carmen  (10)
SAUSSEZ, Sven  (8)
COLET, Jean-Marie  (7)
JOURNE, Fabrice  (7)
Main Referenced Keywords
apoptosis (7); EGFR (6); anaplastic thyroid carcinoma (5); therapeutic peptide (5); targeted therapy (4);
Main Referenced Unit & Research Centers
CMMI - Centre de Recherche en Microscopie et Imagerie Médicale (10)
Main Referenced Disciplines
Oncology (8)
Pharmacy, pharmacology & toxicology (7)
Endocrinology, metabolism & nutrition (6)
Biochemistry, biophysics & molecular biology (6)
Zoology (4)

Publications (total 19)

The most downloaded
214 downloads
Colet, J.-M., Pamart, L., Tagliatti, V., Delsinne, V., & Kahvecioglu, Z. C. (2019). Biologie Générale Humaine : Travaux pratiques. https://hdl.handle.net/20.500.12907/14081

The most cited

11 citations (Scopus®)

Benourad, F., Kahvecioglu, Z. C., Youcef-Benkada, M., & Colet, J.-M. (12 February 2014). Prospective evaluation of potential toxicity of repeated doses of Thymus vulgaris L. extracts in rats by means of clinical chemistry, histopathology and NMR-based metabonomic approach. Drug Testing and Analysis, 6 (10), 1069-75. doi:10.1002/dta.1606 https://hdl.handle.net/20.500.12907/28266

Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Sarah Peeters, Daubry, A., Laurent, S., Saussez, S., & Burtea, C. (06 February 2024). Toward the development of a novel drug using engineered peptides designed for EGFR-mediated drug delivery of an apoptosis inducer in anaplastic thyroid carcinoma [Paper presentation]. Télévie Seminar.

Andre, S., Verteneuil, S., Ris, L., Kahvecioglu, Z. C., Nonclercq, D., De winter, J., Vander elst, L., Laurent, S., Muller, R., & Burtea, C. (29 December 2023). Modulation of Cytosolic Phospholipase A2 as a Potential Therapeutic Strategy for Alzheimer’s Disease. Journal of Alzheimer's Disease Reports, 7 (1), 1395-1426. doi:10.3233/adr-230075
Peer Reviewed verified by ORBi

Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Peeters, S., Daubry, A., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (24 November 2023). Innovative drug delivery system using EGFR-targeted engineered peptides in anaplastic thyroid cancer treatment [Poster presentation]. PhD Day SFMBBM 2023, Liège, Belgium.
Peer reviewed

Kahvecioglu, Z. C., Vandecasteele, S., Bougard, M., Rogien, C., Daubry, A., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (27 October 2023). Novel therapeutic approaches for EGFR-mediated drug delivery using engineered peptides in anaplastic thyroid cancer [Poster presentation]. Annual BACR Meeting 2023 Friday October 27th, CIRCADIAN CYCLE, CHRONOBIOLOGY AND CANCER, brussels, Belgium.
Peer reviewed

Kahvecioglu, Z. C., Samuel Vandecasteele, Marine Bougard, Charlotte Rogien, Journe, F., Laurent, S., Saussez, S., & Burtea, C. (02 July 2023). Development of a novel EGFR-targeted peptide for targeted delivery of drugs in anaplastic thyroid cancer [Poster presentation]. PBA 2023 33rd International Symposium on Pharmaceutical and Biomedical Analysis, ankara, Turkey.
Peer reviewed

Kahvecioglu, Z. C., Toulehohoun, A., Feudjio Tagny, D., Rogien, C., Vandecasteele, S., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (02 February 2023). A study of combined targeted therapy and delivery, inducing an inhibition of PI3K/AKT/mTOR pathway in anaplastic thyroid cancer cells [Paper presentation]. 2023 Télévie Seminar, bruxelles, Belgium.

Kahvecioglu, Z. C., Toulehohoun, A., Feudjio Tagny, D., Rogien, C., Vandecasteele, S., Rogien, C., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (11 September 2022). Novel therapeutic strategy targeting the EGFR and inhibiting PI3K/AKT/mTOR pathway in anaplastic thyroid carcinoma [Poster presentation]. 12th International Symposium on Drug Analysis & 32nd International Symposium on Pharmaceutical and Biomedical Analysis, Mons, Belgium.
Peer reviewed

Kahvecioglu, Z. C., Toulehohoun, A., Feudjio Tagny, D., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (08 April 2022). PI3K/AKT/mTOR pathway inhibition and targeted drug delivery combined in a novel therapeutic strategy addressed to anaplastic thyroid carcinoma [Poster presentation]. Séminaire Télévie.
Peer reviewed

Kahvecioglu, Z. C.* , Bruynbroeck, M., Gheysen, L., Journé, F., Laurent, S., Saussez, S., & Burtea, C.*. (22 September 2021). Delivery of a drug molecule to thyroid cancer cells via EGFR targeting [Poster presentation]. 'Adaptation of the tumour and its ecosystem to radiotherapies' workshop ,September 22nd-25th, 2021, Manoir de Kerdréan, Le Bono, France.
Peer reviewed

Kahvecioglu, Z. C., Gheysen, L., Journe, F., Laurent, S., Saussez, S., & Burtea, C. (21 May 2021). Toward the development of peptide inhibitors targeted to PI3K/AKT signalling pathway for the therapy of anaplastic thyroid carcinoma [Poster presentation]. 27th Porto Cancer meeting Stemness & Metastasis: Advances in Research and Clinical Translation, Porto, Portugal.

Kahvecioglu, Z. C. (2020). Prise en charge du patient atteint d'un carcinome rénal à cellules claires métastatiques: le profil métabonomique prédit-il la réponse au traitement? [Master’s dissertation, Université de Mons]. ORBi UMONS-University of Mons. https://orbi.umons.ac.be/handle/20.500.12907/11808

Colet, J.-M., Pamart, L., Tagliatti, V., Delsinne, V., & Kahvecioglu, Z. C. (2019). Biologie Générale Humaine : Travaux pratiques.

Benourad, F., Kahvecioglu, Z. C., Youcef-Benkada, M., & Colet, J.-M. (09 October 2018). Protective potential of the essential oil of Thymus vulgaris L. against Dicofol-induced poisoning in rats as established through clinical chemistry, histopathology and 1H-NMR-based metabonomics. South Asian Journal of Experimental Biology, 8 (2), 49-56.
Peer reviewed

Maurois, P., Conotte, R., Kahvecioglu, Z. C., & Colet, J.-M. (23 May 2018). Etude par approche métabonomique et histopathologique d'une surconsommation en saccharose chez la souris [Poster presentation]. 11e journées scientifiques du Réseau Francophone de Métabonomique et fluxomique, Liège, Belgium.

Benourad, F., Kahvecioglu, Z. C., Youcef-Benkada, M., & Colet, J.-M. (12 February 2014). Prospective evaluation of potential toxicity of repeated doses of Thymus vulgaris L. extracts in rats by means of clinical chemistry, histopathology and NMR-based metabonomic approach. Drug Testing and Analysis, 6 (10), 1069-75. doi:10.1002/dta.1606
Peer Reviewed verified by ORBi

Hambye, S., Helvenstein, M., Verdy, L., Kahvecioglu, Z. C., Conotte, R., Vanden Eynde, J.-J., Colet, J.-M., & Blankert, B. (10 February 2014). Ultra High Performance Liquid Chromatography method for the determination of Pentamidine and analog in rat biological fluids. Journal of Pharmaceutical and Biomedical Analysis, 95, 54-60.
Peer Reviewed verified by ORBi

Colet, J.-M., Conotte, R., Kahvecioglu, Z. C., & Matuszak, N. (01 September 2009). Long term metabolic changes induced inidiosyncrasy-like liver toxicity [Poster presentation]. 46th Congress of the European Societies of Toxicology - Eurotox 2009, Dresde, Germany.

Colet, J.-M., Laurent, S., Kahvecioglu, Z. C., Boutry, S., Vander Elst, L., & Müller, R. N. (01 September 2009). Vectorization of Iron Oxide Nanoparticles with a Neuron-penetrating RVG Peptide: An Attempt to Cross the Blood Brain Barrier [Paper presentation]. World Molecular Imaging Congress, Montreal, Canada.

Kahvecioglu, Z. C. (2008). Evaluation des effets pharmacologiques et toxiques d'un extrait méthanolique de Sattaga bowal [Master’s dissertation, Université de Mons]. ORBi UMONS-University of Mons. https://orbi.umons.ac.be/handle/20.500.12907/29275

Contact ORBi UMONS